Satsuma Pharmaceuticals (STSA) is scheduled to report 1st quarter earnings on 05/22/2023.
Regarding Q1 estimates, Wall Street analysts expect Satsuma Pharmaceuticals to post earnings of -$0.30 per share. Last quarter, Satsuma Pharmaceuticals missed earnings estimates, reporting EPS of -$0.70 on estimates of -$0.36. The stock fell by -8.33% the day after the last earnings release.
Year-to-date, STSA stock has risen by 23.26%.
Is Satsuma Pharmaceuticals Stock a Buy?
Wall Street’s consensus rating for STSA stock is a Hold, with an average analyst price target of $2.00, implying upside potential of 88.68% from current levels.
STSA shares have gained about 63.08% in the past six months.
About Satsuma Pharmaceuticals
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.
Stay up-to-date on earnings this week, with TipRanks’ Earnings Calendar.
